OBJECTIVE: We examined factors associated with survival among patients with newly diagnosed non-Hodgkin lymphoma (NHL) in Uganda. METHODS: Information was abstracted from medical records for all NHL patients >13 years of age at the Uganda Cancer Institute between January 2004 and August 2008. Cox proportional hazard models were used to identify predictors of NHL survival. RESULTS: One hundred sixty patients with NHL were identified; 51 (31.9%) were known to be HIV positive. Overall, 154 patients had records sufficient for further analysis. The median person-time observed was 104 days (interquartile range 26-222). Median survival after presentation among those whose mortality status was confirmed was 61 days (interquartile range 25-203). HIV-positive patients receiving antiretroviral therapy had survival rates approximating those of HIV-negative persons, but the adjusted hazard of death was significantly elevated among HIV-positive patients not receiving antiretroviral therapy [adjusted hazard ratio (HR) 8.99, P < 0.001] compared with HIV-negative patients. Both B-symptoms (HR 2.08, P = 0.05) and female gender (HR 1.72, P = 0.05) were associated with higher mortality. CONCLUSIONS: In Uganda, overall survival of NHL patients is poor, and predictors of survival differed from those described in resource-rich regions. HIV is a common comorbidity to NHL, and its lack of treatment was among the strongest predictors of mortality. Strategies are needed for optimal management of HIV-infected individuals with cancer in resource-limited settings.
OBJECTIVE: We examined factors associated with survival among patients with newly diagnosed non-Hodgkin lymphoma (NHL) in Uganda. METHODS: Information was abstracted from medical records for all NHLpatients >13 years of age at the Uganda Cancer Institute between January 2004 and August 2008. Cox proportional hazard models were used to identify predictors of NHL survival. RESULTS: One hundred sixty patients with NHL were identified; 51 (31.9%) were known to be HIV positive. Overall, 154 patients had records sufficient for further analysis. The median person-time observed was 104 days (interquartile range 26-222). Median survival after presentation among those whose mortality status was confirmed was 61 days (interquartile range 25-203). HIV-positivepatients receiving antiretroviral therapy had survival rates approximating those of HIV-negative persons, but the adjusted hazard of death was significantly elevated among HIV-positivepatients not receiving antiretroviral therapy [adjusted hazard ratio (HR) 8.99, P < 0.001] compared with HIV-negative patients. Both B-symptoms (HR 2.08, P = 0.05) and female gender (HR 1.72, P = 0.05) were associated with higher mortality. CONCLUSIONS: In Uganda, overall survival of NHLpatients is poor, and predictors of survival differed from those described in resource-rich regions. HIV is a common comorbidity to NHL, and its lack of treatment was among the strongest predictors of mortality. Strategies are needed for optimal management of HIV-infected individuals with cancer in resource-limited settings.
Authors: S C Remick; N Sedransk; R F Haase; C G Blanchard; C R Ramnes; T Nazeer; D M Mastrianni; B J Dezube Journal: Am J Hematol Date: 2001-03 Impact factor: 10.047
Authors: Mark Bower; Brian Gazzard; Sundhiya Mandalia; Tom Newsom-Davis; Christina Thirlwell; Tony Dhillon; Anne Marie Young; Tom Powles; Andrew Gaya; Mark Nelson; Justin Stebbing Journal: Ann Intern Med Date: 2005-08-16 Impact factor: 25.391
Authors: S Smeland; A K Blystad; S O Kvaløy; I M Ikonomou; J Delabie; G Kvalheim; J Hammerstrøm; G F Lauritzsen; H Holte Journal: Ann Oncol Date: 2004-07 Impact factor: 32.976
Authors: M C Robotin; M G Law; S Milliken; D Goldstein; R J Garsia; G M Dolan; J M Kaldor; A E Grulich Journal: HIV Med Date: 2004-09 Impact factor: 3.180
Authors: Michalina A Montaño; Maganizo B Chagomerana; Margaret Borok; Matthew Painschab; Thomas S Uldrick; Rachel A Bender Ignacio Journal: Curr HIV/AIDS Rep Date: 2021-02-02 Impact factor: 5.071
Authors: Satish Gopal; William A Wood; Stephanie J Lee; Thomas C Shea; Kikkeri N Naresh; Peter N Kazembe; Corey Casper; Peter B Hesseling; Ronald T Mitsuyasu Journal: Blood Date: 2012-03-28 Impact factor: 22.113
Authors: Matthew S Painschab; Edwards Kasonkanji; Takondwa Zuze; Bongani Kaimila; Tamiwe Tomoka; Richard Nyasosela; Ruth Nyirenda; Bal M Dhungel; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Wilberforce Mhango; Fred Chimzimu; Coxcilly Kampani; Robert Krysiak; Thomas C Shea; Nathan D Montgomery; Yuri Fedoriw; Satish Gopal Journal: Br J Haematol Date: 2018-11-18 Impact factor: 6.998
Authors: Anna E Coghill; Polly A Newcomb; Margaret M Madeleine; Barbra A Richardson; Innocent Mutyaba; Fred Okuku; Warren Phipps; Henry Wabinga; Jackson Orem; Corey Casper Journal: AIDS Date: 2013-11-28 Impact factor: 4.177